ACCELERON PHARMA INC Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
Revenue:
Collaboration revenue:
License and milestone
Revenue
Milestone
Cost-sharing, net
Royalty
Total revenue

Costs and expenses:
Research and development
Litigation settlement
Selling, general and administrative
Total costs and expenses

Loss from operations
Other (expense) income, net
Interest expense
Interest income
Other income, net
Loss before income taxes
Income tax (provision) benefit
Net loss
Other comprehensive income (loss):
Net unrealized holding (losses) gains on short- and long-term investments during the period, net of tax
Comprehensive loss
Net loss per share- basic and diluted (in dollars per share)
Weighted-average number of common shares used in computing net loss per share-basic and diluted (in shares)

Comments